Arovella Therapeutics Limited (ALA.AX)
AUD 0.18
(5.88%)
AUD 0.18
(5.88%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 | -12.71 Million AUD | -145.67% |
| 2023 | -5.17 Million AUD | 12.67% |
| 2022 | -5.92 Million AUD | 10.72% |
| 2021 | -6.63 Million AUD | -644.16% |
| 2020 | -892.01 Thousand AUD | 79.06% |
| 2019 | -4.26 Million AUD | -318.32% |
| 2018 | 1.95 Million AUD | 5869.95% |
| 2017 | 32.68 Thousand AUD | 104.55% |
| 2016 | -718.77 Thousand AUD | 84.12% |
| 2015 | -4.52 Million AUD | -114.0% |
| 2014 | -2.11 Million AUD | -616.73% |
| 2013 | 409.38 Thousand AUD | 146.05% |
| 2012 | -889 Thousand AUD | 61.03% |
| 2011 | -2.28 Million AUD | -297.69% |
| 2010 | 1.15 Million AUD | -16.17% |
| 2009 | 1.37 Million AUD | -56.95% |
| 2008 | 3.19 Million AUD | -2.58% |
| 2007 | 3.28 Million AUD | 103.83% |
| 2006 | 1.61 Million AUD | 160.42% |
| 2005 | 618.34 Thousand AUD | 134.49% |
| 2004 | -1.79 Million AUD | -496.85% |
| 2003 | -300.42 Thousand AUD | 47.93% |
| 2002 | -577 Thousand AUD | 86.65% |
| 2001 | -4.32 Million AUD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q4 | -12.71 Million AUD | 0.0% |
| 2024 Q2 | -4.76 Million AUD | 0.0% |
| 2024 FY | -12.71 Million AUD | -145.67% |
| 2024 Q3 | -12.71 Million AUD | -166.92% |
| 2024 Q1 | -4.76 Million AUD | 19.62% |
| 2023 Q2 | -3.47 Million AUD | 1.06% |
| 2023 Q3 | -5.17 Million AUD | -48.95% |
| 2023 Q4 | -5.92 Million AUD | -14.51% |
| 2023 FY | -5.17 Million AUD | 12.67% |
| 2023 Q1 | -3.51 Million AUD | 40.74% |
| 2022 Q1 | -4.27 Million AUD | 35.61% |
| 2022 FY | -5.92 Million AUD | 10.72% |
| 2022 Q4 | -5.92 Million AUD | 1.12% |
| 2022 Q3 | -5.99 Million AUD | -42.33% |
| 2022 Q2 | -4.21 Million AUD | 1.47% |
| 2021 Q1 | -5.43 Million AUD | -508.86% |
| 2021 Q4 | -6.63 Million AUD | 1.14% |
| 2021 Q3 | -6.71 Million AUD | -25.38% |
| 2021 FY | -6.63 Million AUD | -644.16% |
| 2021 Q2 | -5.35 Million AUD | 1.39% |
| 2020 Q2 | -2.25 Million AUD | 4.06% |
| 2020 Q3 | -973.23 Thousand AUD | 56.79% |
| 2020 FY | -892.01 Thousand AUD | 79.06% |
| 2020 Q4 | -892.01 Thousand AUD | 8.35% |
| 2020 Q1 | -2.34 Million AUD | 44.9% |
| 2019 Q3 | -4.29 Million AUD | -56.31% |
| 2019 Q2 | -2.74 Million AUD | 0.0% |
| 2019 FY | -4.26 Million AUD | -318.32% |
| 2019 Q1 | -2.74 Million AUD | -240.86% |
| 2019 Q4 | -4.26 Million AUD | 0.84% |
| 2018 Q1 | 1.42 Million AUD | 4274.42% |
| 2018 Q2 | 1.42 Million AUD | 0.0% |
| 2018 Q4 | 1.95 Million AUD | 1.08% |
| 2018 Q3 | 1.93 Million AUD | 35.01% |
| 2018 FY | 1.95 Million AUD | 5869.95% |
| 2017 Q3 | 32.68 Thousand AUD | -93.59% |
| 2017 FY | 32.68 Thousand AUD | 104.55% |
| 2017 Q4 | 32.68 Thousand AUD | 0.0% |
| 2017 Q2 | 510.16 Thousand AUD | 0.0% |
| 2017 Q1 | 510.16 Thousand AUD | 170.98% |
| 2016 Q4 | -718.77 Thousand AUD | 0.0% |
| 2016 Q1 | -1.66 Million AUD | 63.21% |
| 2016 Q3 | -718.77 Thousand AUD | 56.85% |
| 2016 Q2 | -1.66 Million AUD | 0.0% |
| 2016 FY | -718.77 Thousand AUD | 84.12% |
| 2015 Q2 | -1.17 Million AUD | 0.0% |
| 2015 FY | -4.52 Million AUD | -114.0% |
| 2015 Q4 | -4.52 Million AUD | 0.0% |
| 2015 Q3 | -4.52 Million AUD | -285.37% |
| 2015 Q1 | -1.17 Million AUD | 44.47% |
| 2014 FY | -2.11 Million AUD | -616.73% |
| 2014 Q2 | -2.74 Million AUD | 0.0% |
| 2014 Q3 | -2.11 Million AUD | 22.92% |
| 2014 Q1 | -2.74 Million AUD | -770.37% |
| 2014 Q4 | -2.11 Million AUD | 0.0% |
| 2013 Q2 | -1.06 Million AUD | 0.0% |
| 2013 Q3 | 409.38 Thousand AUD | 138.38% |
| 2013 Q4 | 409.38 Thousand AUD | 0.0% |
| 2013 FY | 409.38 Thousand AUD | 146.05% |
| 2013 Q1 | -1.06 Million AUD | -20.0% |
| 2012 Q4 | -889 Thousand AUD | 0.0% |
| 2012 FY | -889 Thousand AUD | 61.03% |
| 2011 FY | -2.28 Million AUD | -297.69% |
| 2011 Q4 | -2.36 Million AUD | 0.0% |
| 2010 FY | 1.15 Million AUD | -16.17% |
| 2010 Q4 | 1.15 Million AUD | 0.0% |
| 2009 FY | 1.37 Million AUD | -56.95% |
| 2009 Q4 | 1.37 Million AUD | 0.0% |
| 2008 Q4 | 2.96 Million AUD | 0.0% |
| 2008 FY | 3.19 Million AUD | -2.58% |
| 2007 Q4 | 3.28 Million AUD | 0.0% |
| 2007 FY | 3.28 Million AUD | 103.83% |
| 2006 FY | 1.61 Million AUD | 160.42% |
| 2006 Q4 | 1.61 Million AUD | 0.0% |
| 2005 FY | 618.34 Thousand AUD | 134.49% |
| 2005 Q4 | 618.34 Thousand AUD | 0.0% |
| 2004 FY | -1.79 Million AUD | -496.85% |
| 2004 Q4 | -1.79 Million AUD | 0.0% |
| 2003 Q4 | -301.92 Thousand AUD | 0.0% |
| 2003 FY | -300.42 Thousand AUD | 47.93% |
| 2002 FY | -577 Thousand AUD | 86.65% |
| 2001 FY | -4.32 Million AUD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| EZZ Life Science Holdings Limited | -18.89 Million AUD | 32.724% |
| Anatara Lifesciences Ltd | -982.1 Thousand AUD | -1194.605% |
| Zelira Therapeutics Limited | 5.06 Million AUD | 350.909% |
| Biome Australia Limited | -1.56 Million AUD | -713.562% |
| Patrys Limited | -2.24 Million AUD | -467.44% |
| Orthocell Limited | -19.92 Million AUD | 36.188% |
| Imugene Limited | -91.56 Million AUD | 86.114% |
| Noxopharm Limited | -2.31 Million AUD | -448.052% |
| PYC Therapeutics Limited | -65.76 Million AUD | 80.666% |
| Chimeric Therapeutics Limited | -3.05 Million AUD | -316.456% |
| Prescient Therapeutics Limited | -10.16 Million AUD | -25.109% |
| Proteomics International Laboratories Limited | -6.32 Million AUD | -101.055% |
| Cynata Therapeutics Limited | -6.2 Million AUD | -104.892% |
| CSL Limited | 15.76 Billion AUD | 100.081% |
| Bio-Gene Technology Limited | -709.55 Thousand AUD | -1691.877% |
| Clinuvel Pharmaceuticals Limited | -182.98 Million AUD | 93.052% |
| Starpharma Holdings Limited | -19.83 Million AUD | 35.889% |
| Nanollose Limited | -96.22 Thousand AUD | -13113.206% |
| Memphasys Limited | 4.13 Million AUD | 407.455% |
| Invex Therapeutics Ltd | -6.02 Million AUD | -111.025% |
| NeuroScientific Biopharmaceuticals Limited | -4.95 Million AUD | -156.642% |
| Amplia Therapeutics Limited | -1.82 Million AUD | -597.218% |
| Botanix Pharmaceuticals Limited | -79.3 Million AUD | 83.968% |
| Island Pharmaceuticals Limited | -1.23 Million AUD | -926.673% |
| Race Oncology Limited | -17.18 Million AUD | 26.031% |
| Nyrada Inc. | -4.76 Million AUD | -166.584% |
| Telix Pharmaceuticals Limited | -105.79 Million AUD | 87.982% |
| Dimerix Limited | -21.99 Million AUD | 42.186% |
| PharmAust Limited | -9.71 Million AUD | -30.886% |
| Immutep Limited | -122.18 Million AUD | 89.595% |
| Clarity Pharmaceuticals Ltd | -136.5 Million AUD | 90.686% |
| Alterity Therapeutics Limited | -12.47 Million AUD | -1.88% |
| BTC Health Limited | -2.02 Million AUD | -528.755% |
| Acrux Limited | -1.45 Million AUD | -772.044% |
| Neuren Pharmaceuticals Limited | -17.09 Million AUD | 25.621% |
| Biotron Limited | -386.06 Thousand AUD | -3193.308% |
| Tissue Repair Ltd | -16.44 Million AUD | 22.667% |
| AdAlta Limited | -845.17 Thousand AUD | -1404.356% |
| Radiopharm Theranostics Limited | -18.57 Million AUD | 31.551% |
| Hexima Limited | -2.22 Million AUD | -471.122% |
| AnteoTech Limited | -5 Million AUD | -154.211% |
| Paradigm Biopharmaceuticals Limited | -17.58 Million AUD | 27.683% |
| Recce Pharmaceuticals Ltd | -3.39 Million AUD | -274.379% |
| Avecho Biotechnology Limited | -5.32 Million AUD | -138.578% |
| Actinogen Medical Limited | -9.13 Million AUD | -39.234% |
| Immuron Limited | -11.48 Million AUD | -10.716% |
| Argenica Therapeutics Limited | -15.91 Million AUD | 20.099% |